Vaccines for HIV Prevention
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on medications that might impair your immune response, such as certain systemic medications, you may need to discuss this with the trial team.
What data supports the effectiveness of the treatment 16055 NFL Delta Gly4 Env Protein Trimer, Ad4-Env145NFL Viral Particles, Trimer 4571 for HIV prevention?
Research on similar HIV vaccine components, like stabilized Env trimers, shows they can induce strong antibody responses, which are crucial for protection against HIV. Studies have demonstrated that combinations of different Env trimers can enhance the immune response, suggesting that the treatment may be effective in generating protective antibodies.12345
Is the HIV vaccine candidate safe for humans?
How does the treatment 16055 NFL Delta Gly4 Env Protein Trimer, Ad4-Env145NFL Viral Particles, Trimer 4571 differ from other HIV prevention treatments?
This treatment is unique because it uses a trimeric form of the HIV envelope protein, which better mimics the natural structure of the virus and is designed to induce a stronger immune response by generating broadly neutralizing antibodies. Unlike previous vaccines that used monomeric forms, this approach aims to improve the effectiveness against diverse HIV strains.257910
What is the purpose of this trial?
The goal of this clinical trial is to test 16055 NFL delta Gly4 Env protein trimer and Trimer 4571 combined with 3M-052-AF + Alum adjuvant and Ad4-Env145NFL viral particles as heterologous prime-boost regimens in adult participants without HIV.The main question\[s\] it aims to answer are:* Are these vaccine regimens safe and well tolerated?* Are the prime-boost vaccine regimens that include Ad4-Env145NFL and Trimer 4571 as heterologous boosts going contribute to the development of B-cell and antibody responses?Participants will attend scheduled study visits to receive their vaccine and will record symptoms on a daily eDiary.
Eligibility Criteria
This trial is for adults without HIV who are interested in testing new vaccine regimens aimed at preventing HIV/AIDS. Participants must attend scheduled visits and keep a daily eDiary of symptoms.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the study vaccines as heterologous prime-boost regimens at months 0, 2, 4, 8, and 12
Follow-up
Participants are monitored for safety and effectiveness after treatment, including antibody response measurements
Treatment Details
Interventions
- 16055 NFL Delta Gly4 Env Protein Trimer
- Ad4-Env145NFL Viral Particles
- Trimer 4571
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor